Roth Capital Forecasts Weaker Earnings for Journey Medical

Journey Medical Co. (NASDAQ:DERM - Free Report) - Equities research analysts at Roth Capital reduced their Q1 2025 earnings per share estimates for shares of Journey Medical in a report issued on Thursday, March 27th. Roth Capital analyst J. Wittes now expects that the company will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical's Q2 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.05 EPS, FY2026 earnings at $2.18 EPS, FY2027 earnings at $3.32 EPS and FY2028 earnings at $5.18 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The firm had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.21 million.

DERM has been the subject of a number of other reports. Industrial Alliance Securities set a $10.50 price target on Journey Medical in a report on Thursday, March 27th. Alliance Global Partners reissued a "buy" rating on shares of Journey Medical in a report on Thursday, March 27th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $9.88.

Journey Medical Stock Performance

DERM traded up $0.35 on Monday, hitting $6.59. The company's stock had a trading volume of 80,509 shares, compared to its average volume of 85,448. The company's 50 day simple moving average is $5.29 and its 200-day simple moving average is $5.20. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical has a 12 month low of $3.20 and a 12 month high of $6.89. The firm has a market cap of $137.67 million, a P/E ratio of -7.01 and a beta of 0.90.

Insider Activity

In related news, CEO Claude Maraoui sold 49,271 shares of Journey Medical stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71. Following the completion of the sale, the chief executive officer now owns 2,003,147 shares of the company's stock, valued at approximately $10,035,766.47. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 105,831 shares of company stock worth $536,622 in the last three months. Corporate insiders own 13.16% of the company's stock.

Hedge Funds Weigh In On Journey Medical

A number of institutional investors have recently added to or reduced their stakes in DERM. Cetera Investment Advisers boosted its position in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after acquiring an additional 2,478 shares during the last quarter. PVG Asset Management Corp lifted its position in Journey Medical by 5.7% during the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock valued at $947,000 after purchasing an additional 9,005 shares during the last quarter. Kovitz Investment Group Partners LLC bought a new stake in Journey Medical during the third quarter valued at approximately $66,000. Geode Capital Management LLC grew its stake in Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock worth $613,000 after buying an additional 12,882 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Journey Medical in the 4th quarter worth $80,000. 7.25% of the stock is currently owned by institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.